Compare Meta Platforms Inc (META) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Meta Platforms Inc trades at $729.01 (market cap $1.94T), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Meta Platforms Inc is far larger — about 397.5× Travere Therapeutics Inc. Common Stock's market cap, and Meta Platforms Inc pays a 0.28% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 128 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| META | TVTX | |
|---|---|---|
Market Cap | $1.94T | $4.88B |
Volume | 22,627,792 | 1,668,577 |
Sector | Media | Health |
52-Week High | $777.59 | $67.52 |
52-Week Low | $525.72 | $26.79 |
Typical Hold Time | 128 Days | 0 Days |
Enterprise Value | $1.96T | $5.01B |
Dividend Yield | 0.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $737.54, down 0.73% on the day, with strong bullish technical signals from moving averages and ADX indicators. The company demonstrates robust fundamentals with $201B revenue in 2025, 29.8% net margin, and consistent earnings beats in recent quarters. Recent AI developments including Muse Spark launch and a $21B CoreWeave deal highlight growth initiatives.
Wall Street maintains strong bullish sentiment with 80% buy ratings and $802.80 consensus target, representing 9% upside. Key risks include ongoing youth addiction litigation in Massachusetts and elevated capital expenditures for AI infrastructure. The stock presents growth potential through AI monetization but faces regulatory and execution challenges.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
